Drug Database
SU

sultosilic acid piperazine (Mimedran)

✓ Approved

Esteve · LPL · 小分子

什么是 sultosilic acid piperazine?

sultosilic acid piperazine 是一种小分子,由Esteve研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Mimedran
公司Esteve
药物类别小分子
分子靶点LPL
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

sultosilic acid piperazine 作用于 1 个分子靶点:

LPLlipoprotein lipase (HDLCQ11, LIPD)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sultosilic acid piperazine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

相关研究文献

PubMedMolecules (Basel, Switzerland)2026-10-27

Synthesis of Arylpiperazine-Based CNS Ligands: Batch Disconnections and Their Continuous-Flow Implementation.

Jeong Daeun D, Han Ji Myoung JM, Lee Ji Hoo JH, Oh In Young IY et al.

The 1-arylpiperazine unit recurs throughout centrally acting drugs, particularly ligands of serotonin and dopamine receptors, where its modular architecture-aryl group, piperazine core, linker, terminal fragment-has made it a durable design template. Three principal intermodule disconnections-the aryl-nitrogen bond, the piperazine-linker bond, and the linker-terminal bond-provide an organizing framework for the routes reviewed here. This review compares representative batch routes with reported continuous-flow implementations, distinguishing related methodological precedents, individual transformations in drug-specific routes, and linked multistep sequences. Three observations emerge from the reviewed examples. First, the drug-directed flow routes examined use preformed arylpiperazine building blocks. Second, dechlorination reported during cariprazine reductive amination highlights the importance of catalyst and solvent selection for that substrate. Third, the reported flow implementations address selected process challenges, while the multistep examples highlight the importance of compatibility between reaction and work-up operations. These observations inform a practical framework for evaluating batch and flow options for individual routes.

PMID 42943752
阅读全文 →
PubMedMolecules (Basel, Switzerland)2026-10-27

Pyridine-3-Carboxamide-1,3,4-Thiadiazole Hybrids as Antimicrobial Agents: Synthesis, Biological Evaluation, In Vivo Toxicity, and Computational Studies.

Świątek Piotr P, Strzelecka Małgorzata M, Szczukowski Łukasz Ł, Jezierska Aneta A et al.

The rapid emergence of antimicrobial resistance necessitates the development of novel antimicrobial agents with improved efficacy and favorable safety profiles. In this study, a new series of pyridine-3-carboxamide-1,3,4-thiadiazole hybrids and their corresponding N-Mannich bases bearing structurally diverse piperazine substituents were designed, synthesized, and characterized by FT-IR, 1H/13C NMR, and HR-MS. Their antimicrobial activity was evaluated against reference and clinical bacterial and fungal strains using broth microdilution and agar diffusion assays. The compounds exhibited selective activity against Gram-positive bacteria, with minimum inhibitory concentrations of 0.034-0.069 mg/mL against Staphylococcus aureus ATCC 33591 and bactericidal effects reflected by MBC values comparable to MICs. No activity was observed against Pseudomonas aeruginosa or Candida albicans, and the compounds were ineffective in eradicating preformed staphylococcal biofilms. In vivo toxicity studies using the Galleria mellonella model indicated no-to-low apparent acute toxicity under the applied experimental conditions for most derivatives. DFT and QTAIM analyses revealed substituent-dependent electronic and conformational differences, while molecular docking identified DNA gyrase as the most likely molecular target, with compounds 6 and 7 showing the strongest predicted binding. These results identify pyridine-3-carboxamide-1,3,4-thiadiazole Mannich bases as promising leads for developing new antibacterial agents against Gram-positive pathogens.

PMID 42943773
阅读全文 →
PubMedJournal of the American Chemical Society2026-10-27

Self-Catalyzed Transesterification Transforms Ionizable Amphiphilic Janus Dendrimers into Multicomponent Vectors and Generates Complex Design Strategies for mRNA Delivery.

Lu Juncheng J, Atochina-Vasserman Elena N EN, Sahoo Dipankar D, Maurya Devendra S DS et al.

Genetic nanomedicine delivers nucleic acids by viral and synthetic vectors to produce drugs directly in the body's own cells. Each approach presents relative advantages, but synthetic vectors are distinguished by their effectively unlimited synthetic capabilities. The leading synthetic vectors are the four-component lipid nanoparticles (LNPs) used in the Pfizer and Moderna Covid-19 vaccines, which deliver mRNA to the liver. Inspired by this concept, our laboratories developed a one-component, multifunctional, sequence-defined ionizable amphiphilic Janus dendrimer (IAJD) that delivers mRNA predominantly to the more desirable spleen, as well as to other organs. Benzoyl, benzyl, and aliphatic biodegradable esters connect the hydrophobic and hydrophilic domains of IAJDs. IAJDs have already been used in preclinical studies of therapeutics and vaccines, and several are commercially available. Here we report that, unexpectedly, the least stable benzyl-ester-based IAJDs, which contain the 1-(2-hydroxyethyl)piperazine ionizable amine (IA), undergo an extraordinarily slow, self-catalyzed transesterification at room temperature that transforms the one-component system into a multicomponent one. This reaction progressively extends the hydrophilic ionizable-amine domain from monomer to dimer, trimer, tetramer, and pentamer, generating a mixture of the original IAJD, its oligomers, and the released benzyl alcohol. Remarkably, at up to 50% transesterification, the in vivo activity of this multicomponent system remains similar to that of the parent one-component IAJD. Beyond providing a simple in situ method to convert one-component IAJDs into an unprecedented multicomponent IAJDs system, these results establish a new design strategy to construct the hydrophilic domain of one-component IAJDs through a complex, "vertical", sequence-defined arrangement of IAs.

PMID 42937890
阅读全文 →
PubMedMicroorganisms2026-10-27

Shotgun Metagenomics Reveals Systemic Metabolic Pathways Promoting Organic Acid Production in Traditional Sunki Fermentation.

Oshima Asahi A, Sekiguchi Sona S, Uchikawa Shogo S, Fujita Naoya N et al.

Salt-free lacto-fermentation is gaining attention owing to the global demand for sodium reduction. Sunki, a traditional unsalted Japanese turnip pickle, provides a unique ecological model. In this study, we investigated the microbial balance and systemic metabolic pathways that promote organic acid accumulation using shotgun metagenomics. We revealed that a high-quality sunki cluster exhibiting an abundant accumulation of organic acids (lactic acid 8.58 ± 2.42 g/L, acetic acid 2.70 ± 0.76 g/L, succinic acid 1.50 ± 0.52 g/L) and low pH (3.91 ± 0.15) was characterized by the co-dominance of specific lactic acid bacteria along with the foundational species Limosilactobacillus fermentum. This co-dominance enables the synergistic operation of both the homofermentative and heterofermentative pathways, whose functional potentials positively correlated with lactic acid (r = 0.50) and acetic acid (r = 0.48) concentrations, respectively, thereby achieving both effective preservation and flavor complexity. Furthermore, we propose a dual-pathway model for succinic acid production involving the reductive tricarboxylic acid cycle from malate and the γ-aminobutyric acid (GABA) shunt. Succinic acid positively correlated with the functional potential of the GABA shunt enzyme (puuE, r = 0.57) and negatively correlated with that of glutamate dehydrogenase (gdhA, r = -0.51), suggesting a metabolic switch redirecting glutamate flux toward the GABA shunt. This mechanism highlights an advanced ecological adaptation for pH homeostasis, emphasizing that a balanced co-dominance structure determines the quality of salt-free fermented foods.

PMID 42943633
阅读全文 →
PubMedPharmaceuticals (Basel, Switzerland)2026-10-27

The Network Pharmacology of Rosmarinic Acid and Elucidating the Wound Healing Potential of a Rosmarinic Acid-Enriched Trachystemon orientalis Extract.

Badem Merve M, Kanbolat Şeyda Ş, Ulas Çolak Nevin N, Subaş Tuğba T et al.

Background/Objectives:Trachystemon orientalis (L.) D. Don has been reported to be used in folk medicine for the treatment of inflammatory wounds and for its contained rosmarinic acid, a phenolic compound known for its antioxidant, anti-inflammatory, antimicrobial, and wound healing properties. This study aimed to obtain a rosmarinic acid-enriched extract from the aerial parts of T. orientalis and evaluate its in vitro wound healing potential. Methods: Extraction conditions were optimized using fractional factorial design and Box-Behnken optimization. Rosmarinic acid content was quantified by RP-HPLC. A rosmarinic acid-enriched extract was compared with a maceration extract and isolated rosmarinic acid. Elastase, hyaluronidase, and collagenase inhibitory activities were determined. Cytotoxicity was evaluated on L929 fibroblasts using the MTT assay, and non-cytotoxic concentrations were assessed for their effects on in vitro wound healing by scratch assay. In addition, in silico target prediction and network pharmacology analyses were performed using rosmarinic acid. Results: Optimization successfully yielded a rosmarinic acid-enriched extract from T. orientalis. The rosmarinic acid-enriched extract inhibited wound-related enzymes and enhanced wound closure in the scratch assay. Network pharmacology analysis showed putative molecular targets and signaling pathways potentially associated with the wound healing activity of rosmarinic acid, especially those involved in inflammatory responses, extracellular matrix remodeling, and tissue regeneration. Conclusions: The rosmarinic acid-enriched extract exhibited promising in vitro wound healing-related activity through the inhibition of extracellular matrix degrading enzymes and promotion of wound closure. Furthermore, network pharmacology analysis provided preliminary mechanistic insights based on computational predictions.

PMID 42943331
阅读全文 →
PubMedMolecules (Basel, Switzerland)2026-10-27

Bi-O-S Catalyst for Enhanced CO2 Electroreduction to Formic Acid: Catalyst-Substrate Engineering and Multi-Objective Optimization.

Geetha Mithra M, Ghazi Zeyad M ZM, Arsalan Muhammad M, El-Naas Muftah H MH

Electrochemical CO2 reduction to formic acid is a promising approach for carbon valorization, but achieving both high productivity and Faradaic efficiency remains a major challenge. In this study, a Bi-O-S electrocatalyst was synthesized and deposited onto an acid-treated Sn substrate to fabricate a Bi-O-S/acid-treated Sn electrode. Structural, chemical, morphological, and textural characterization confirmed successful formation and integration of the Bi-O-S catalytic phase with the Sn surface. Acid treatment of the electrode surface enhanced the formic acid concentration from 170 mg L-1 for untreated Sn to 750 mg L-1. Central composite design coupled with response surface methodology was subsequently employed to optimize applied current density, catholyte concentration, and catalyst loading. Multi-objective optimization experimentally achieved 1020 mg L-1 formic acid and 67% Faradaic efficiency, compared with predicted values of 950 mg L-1 and 61%, respectively, corresponding to a production rate of 41 mg h-1. The electrode maintained stable performance for 33 h, demonstrating the potential of Bi-O-S/acid-treated Sn electrode engineering for efficient and optimized CO2-to-formic-acid conversion.

PMID 42943787
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多sultosilic acid piperazine